Hot-melt extrusion (HME) is an advantageous method for enhancing the solubility and bioavailability of poorly soluble active pharmaceutical ingredients (APIs) — if the formulation is robust and scalable. Partnering early on with an experienced CDMO can help accelerate the development of optimal, scalable, and patient-centric HME products.
Funding supports advancement of Excalipoint’s proprietary platforms and a pipeline of six differentiated programs with first- or best-in-class potential.
New perfusion‑based adherent cell‑culture bioreactor is designed to scale cell therapy manufacturing with integrated process monitoring and automated harvesting.
Brainin brings a combination of cardiovascular medicine, clinical research, and venture investing experience across EU and U.S. biotechnology companies.
International Process Plants (IPP) announces a direct path into commercial volume small molecule API manufacturing for pharmaceutical & CDMO companies at its Grimsby, UK platform—without the capital burden of acquisition or greenfield buildout.
